Annual Meeting Late Breaking Abstracts


Annual Meeting | Registration | Continuing Education | Housing and Travel | Schedule

Late-Breaking Abstracts

Monday, March 26
2:30 p.m. – 3:30 p.m.
Hyatt Regency New Orleans
Celestin Ballroom

Marcela del Carmen, MD, Massachusetts General Hospital/Harvard University, Boston, MA
Amir Jazaeri, MD, The University of Texas MD Anderson Cancer Center, Houston, TX

Late-breaking abstracts

  • Phase III Randomized Trial of Laparoscopic or Robotic vs. Abdominal Radical Hysterectomy in Patients with Early-Stage Cervical Cancer: LACC Trial
    P.T. Ramirez, M. Frumovitz, R. Pareja, A. Lopez, M. Vieira, R. Ribeiro, A. Buda, X. Yan7, K. Robledo, V. Gebski, R.L. Coleman and A. Obermair 
  • Topacio: Preliminary activity and safety in patients (pts) with platinumresistant
    ovarian cancer (PROC) in a phase 1/2 study of niraparib in combination with pembrolizumab
    P.A. Konstantinopoulos, P. Munster, A. Forero-Torez, R.W. Holloway, L. Schwartzberg, U.A. Matulonis, J. Wang, W. Guo, B. Dezube and S. Vinayak.
  • An open-label, phase II basket study of olaparib and durvalumab (MEDIOLA): Results in germline BRCA-mutated (gBRCAm) platinum-sensitive relapsed (PSR) ovarian cancer (OC)
    Y. Drew, M. de Jonge, S.H. Hong, Y.H. Park, A. Wolfer, J. Brown, M. Ferguson, M.E. Gore, R.H. Alvarez, C. Gresty, H. Angell, K. Meyer, M. Learoyd, M. Tang, M. Lanasa, P. Herbolsheimer and S.M. Domchek.
  • Comparative effectiveness of minimally-invasive staging surgery in women with early-stage cervical cancer
    A. Melamed, L. Chen, N.L. Keating, M.G. del Carmen, J.D. Wright and J.A. Rauh-Hain.